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Relato de Caso
Paradoxical skin reaction with infliximab treatment
Reação cutânea paradoxal com tratamento com infliximabe
Larissa Starling de A. Fernandes, Daniela Martinez, Omar Lupi, Ricardo Barbosa Lima, Carlos José Martins,
Antonio D`Acri
ABSTRACT
Considering the increased utilization of anti-TNF medications in the treatment of inflammatory and
autoimmune diseases, dermatologists should be aware of the possible adverse skin reactions. We
describe a case of inverted psoriasis due to the use of infliximab used in the treatment of inflam-
matory bowel disease.
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RESUMO:
Com o aumento do uso de anti-TNF no tratamento de doenças inflamatórias e auto-imunes, os derma-
tologistas devem estar conscientes da possibilidade de reações cutâneas adversas. Apresentamos um
caso de psoríase invertida devido ao uso de infliximab utilizado no tratamento da doença inflamatória
intestinal.
Palavras-chave: Psoríase. Infliximabe. anti-TNF. Reação Paradoxal. Doenças Inflamatórias
Intestinais.
INTRODUCTION
The anti-TNF-α, including adalimumab and
infliximab, are drugs that have dramatically im-
proved the prognosis of inflammatory bowel dis-
ease (Ulcerative colitis and Crohn's Disease). How-
ever, some concerns have recently emerged on anti-
TNF alpha induced inflammatory skin lesions, such
as psoriasiform and eczematiform, lichenoid erup-
tions and lupus-erythematosus-skin-like. Other rare
complications included neutrophilic dermatoses such
as amicrobial pustulosis, which resembles the in-
verted psoriasis. All of these skin disorders rep-
resent a paradoxical reaction, especially the pso-
riasiform pattern, since anti-TNF-α therapies are
commonly used for psoriasis treatment. Paradoxi-
cal psoriasis is a relevant side effect of anti-TNF-α
therapy with an incidence rate of 5 per 100 person-
years.1,2,3 We report the case of a patient with
Crohn's Disease (CD) treated with infliximab who
presented extensive psoriasiform skin lesions, in-
verse psoriasis-like.
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CASE REPORT
A 56-year-old woman was referred for
evaluation of desquamation involving her face,
neck and scalp during the previous week. Her past
medical history revealed that she had been diag-
nosed with CD ten years previously, with gastric,
duodenal, distal ileum, cecum, colon and, at the
present time, intense perianal involvement. She
did not have any personal or familial history of
psoriasis. She had been treated with mesalazine,
azathioprine and adalimumabe, that was replaced
to infliximab (5mg/kg intravenously) with control
of CD. Two years after infliximab introduction, af-
ter the 9th infusion, the eruption got worse with
severe pruritus and extensive erythematous, scaly
and exudative patches on the face, scalp and neck.
There was progression to the flexural areas on
the trunk and limbs. The nail plates were normal
(Figure 1). Skin lesions became clearly psoriasi-
form coincidentally with an increase in the fre-
quency of infliximab infusions (every 6 weeks).
The inicial clinical diagnostic hypothesis were con-
tact dermatitis, atopic dermatitis, seborrheic der-
matitis and inverse psoriasis. Histopathological
examination of a skin biopsy taken from her neck,
close to the hairline, showed psoriasiform hyper-
plasia with marked parakeratosis, spongiosis exo-
cytosis, superficial inflammatory infiltrate consist-
ing of lymphocytes, eosinophils and necrotic
keratinocytes (Figure 2). Results of laboratory
tests were within normal limits. The clinical and
histopathological findings, and the history of
infliximab therapy led to the diagnosis of a para-
doxical skin reaction inverse psoriasis-like. The
treatment was started with topical betametha-
sone dipropionate, oral prednisone 20mg/day and
oral acitretin 20mg/day. After discussing the case
with the gastroenterologist, infliximab therapy
was discontinued and there was slowly resolu-
tion of cutaneous lesion in 4 months. During this
period skin directed therapy was progressively
reduced. The improvement of the eruption after
stopping infliximab reinforce the role of the antiTNF
as a trigger for this reaction (Figure 3). For the
CD the patient remain using mesalazine and aza-
thioprine. Vedolimumab was added to the therapy
regimen to replace infliximab.
DISCUSSION
The paradoxical induction of psoriasis-like
eruption under anti-TNF-α treatments was first re-
ported by Verea et al in 2004. These side effects, in
particular psoriasis, have been defined "paradoxi-
cal", because anti-TNF-α are commonly used to treat
wild psoriasis. The time between the introduction
of the medication and the appearance of lesions can
range from a few days to many months.1-7 The main
risk factors are female sex, CD, personal or family
history of inflammatory skin diseases, smoking,
treatment with adalimumab, but there is not statis-
tic difference with another anti-TNF-α.2
The triggering of inverse psoriasis as a para-
doxical side effect to treatment with infliximab for
Crohn's disease has been reported in the
literature.3,4,8
Sometimes is difficult to diagnose this para-
doxical reaction at the first visit. In this case our
first hypothesis were contact and seborrheic der-
matitis. We suspected that the eruption was a para-
doxical reaction to infliximab because it was severely
itchy, resembled inverse psoriasis and was refrac-
tory to treatment with topical corticosteroids and
low dose oral prednisone. The patient was treated
with corticosteroids due to our first hypothesis: con-
tact and seborrheic dermatitis. So, a biopsy was
performed revealing a spongiotic and psoriasiform
dermatitis with some elements that suggest a drug
reaction such as the presence of necrotic
keratinocytes in the epidermis and eosinophils and
melanophages in the papilar dermis indicating basal
layer damage, which is more common in drug reac-
tions and may not be present in paradoxical reac-
tions. It's difficult to make the diagnosis with only
histopathological findings.
Our patient denied any treatment of drugs
associated with the development of psoriasis, such
as beta-blockers, lithium, antimalarials, angiotensin-
converting enzyme inhibitors, tetracyclines or non-
steroidal anti-inflammatory agents. Also, she de-
nied symptoms of bacterial or viral infection pre-
ceding the beginning of the eruption and the re-
sults of the laboratory tests were within normal
limits.
Another element that strongly suggest the
role of infliximab as a trigger was the improve-
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Figure 1:  Extensive erythematous, scaly and exudative patches on the face, scalp and neck and flexural areas.
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Figure 2:  Histopathological examination of a skin biopsy taken from her neck, close to the hairline,
showed psoriasiform hyperplasia with marked parakeratosis, spongiosis exocytosis, superficial
inflammatory infiltrate consisting of lymphocytes, eosinophils and necrotic keratinocytes
Figure 3:  The improvement of the eruption after stopping infliximab.
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ment of the eruption after it was stopped. We
and Gastroenterologist Service suspended inflix-
imab because patient was scheduling to receive
a new therapy with vedolimumab, which is indi-
cated for inflamatory bowel disease refractory to
anti-TNF-α. The pathogenesis has not been fully
understood, but it seems that imbalance between
different cytokines and activated inflammatory
pathways can cause the onset and/or the aggra-
vation of these skin lesions. Regarding anti-TNF-α
induced psoriasis, it has been speculated that the
inhibition of TNF-α by antibody drugs may stimu-
late uncontrolled production IFN-α by plasmacy-
toid dendritic cells, inducing the recruitment of T
cells and the secretion of pro-inflammatory
cytokines IL12/23, thereby inducing paradoxical
reactions or psoriasis. The combination therapy
with anti-TNF-α plus immunosupressants is asso-
ciated with a reduced risk of paradoxical psoria-
sis.1-7
In case of development of suggestive psori-
asiform lesions, a dermatology evaluation with
eventual biopsy is mandatory. When patients need
a maintenance therapy for the inflammatory bowel
disease (IBD), a switch to a different anti-TNF-α or
to an immunosuppressant, such as cyclosporine,
methotrexate, could be attempted, according to
the intestinal activity and the previous drug his-
tory. The suspension of the anti-TNF drug associ-
ated with the start of systemic medication for pso-
riasis resulted in higher cure rates: approximately
64% versus 44% when systemic medications
started without suspension of the immunobiologi-
cal agent. A systematic review of 222 patients with
IBD treated with anti-TNF-α, with paradoxical
reaction showed that most were adult women, with
CD treated with infliximab.1,3,9 Paradoxical psori-
asiform reactions can be divided clinically into de
novo psoriasis and exacerbation of preexisting
psoriasis. The first, which is more common and
more extensively described in the literature, oc-
curs in patients without a history of psoriasis who
are receiving TNF-α therapy for another inflamma-
tory disorder. The second can occur with or with-
out changes in the morphology of the lesions.10
This review indicated that the psoriasiform
reactions into de novo psoriasis were more preva-
lent than the typical history previously psoriasis.
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